Clinartis is a strategic partner to pharmaceutical and biotechnology companies seeking agile and experienced support in early clinical development. With a strong foundation in clinical pharmacology and translational science and regulatory expertise, we specialize in the design and execution of integrated early-phase
clinical programs that deliver high-quality data, accelerate timelines, and support global regulatory strategies.

Our team specializes in managing complex Phase I and Phase II trials, where establishing a drug’s safety, pharmacokinetics, and preliminary efficacy is essential. With extensive experience across therapeutic areas, we offer the strategic design, rigorous execution, and targeted analysis needed to confidently guide early-stage compounds toward proof-of-concept and beyond.

Clinartis has successfully conducted a wide range of early-phase clinical studies, including First-in-Human (FIH) trials, single and multiple ascending dose (SAD MAD) studies, bioavailability and bioequivalence studies, drug-drug interaction studies, and exploratory biomarker studies. Our deep understanding of early-phase challenges, from rapid patient recruitment to nuanced dose-escalation strategies, allows us to address potential risks and optimize study outcomes proactively. We work closely with clients to tailor study protocols, ensuring compliance with regulatory standards while aligning with the unique characteristics of each drug candidate. Clinartis’ approach to early development is highly hands-on, with dedicated project teams overseeing every
detail to maintain strict adherence to timelines, budgets, and quality benchmarks.
By leveraging innovative trial methodologies, cutting-edge analytics, and a proactive project management style, Clinartis enables clients to gather high-quality data efficiently and reduce early development risks. Our expertise in early clinical development helps clients make informed decisions with confidence, setting a strong foundation for each drug’s clinical journey and accelerating its progress through the pipeline.

Clinartis: Experts in Early-stage Clinical Drug Development

FIRST IN MAN CLINICAL STUDIES

First-in-man (FIM) clinical studies represent a critical juncture in the development of novel and innovative drugs and biologics, as they mark the initial testing phase in human subjects. These studies are meticulously designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of pioneering interventions. The execution of FIM studies demands rigorous planning and strict adherence to regulatory guidelines, including those set forth by the FDA, to ensure the utmost safety of participants. Researchers must judiciously select participants, typically healthy volunteers, and conduct close monitoring to detect any adverse effects promptly. The data garnered from these studies are invaluable, providing crucial insights into the behavior of these novel treatments within the human body and informing subsequent phases of clinical development.

The success of FIM studies hinges on the expertise and experience of the research team. At Clinartis, our team is well-versed in the complexities of FIM studies, employing advanced methodologies and technologies to enhance study outcomes and prioritize patient safety through rigorous monitoring and ethical oversight. This includes continuous monitoring of vital signs, regular laboratory tests, and comprehensive adverse event reporting. Our safety protocols are designed to quickly identify and address any potential issues, ensuring that all procedures comply with FDA requirements and other regulatory standards. Our collaborative approach involves working closely with leading medical institutions and research organizations, fostering an environment of innovation and excellence. Through our commitment to high standards and patient-centric research, Clinartis is at the forefront of advancing medical science and bringing new, innovative treatments to patients.

SINGLE AND MULTIPLE ASCENDING DOSE STUDIES

Clinartis has extensive experience in the strategic design and operational execution of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies—cornerstone components of first-in-human and early-phase development programs. These studies are critical for characterizing the safety, tolerability, and pharmacokinetics of novel compounds in healthy volunteers or patient populations, and for informing dose selection for subsequent clinical phases.

Our team develops tailored SAD/MAD protocols that incorporate adaptive, data-driven escalation strategies, allowing for efficient identification of maximum tolerated doses and pharmacologically active ranges. We utilize robust dose-escalation frameworks with real-time safety monitoring and predefined stopping rules to ensure participant safety and regulatory compliance.

SAD studies focus on defining initial human exposure and understanding dose-proportionality, while MAD studies assess drug accumulation, steady-state pharmacokinetics, and preliminary pharmacodynamic signals. Clinartis employs validated methodologies, including intensive PK/PD sampling, biomarker integration, and advanced statistical modeling, to support data interpretation and decision-making.

We work closely with high-performing clinical pharmacology units and CRO partners to streamline recruitment, data capture, and compliance with ICH and regional regulatory requirements. Our operational agility and scientific rigor ensure timely delivery of high-quality datasets to support go/no-go decisions, regulatory submissions, and downstream development planning.

Clinartis enables sponsors to confidently advance investigational therapies by delivering SAD and MAD studies that are scientifically robust, operationally efficient, and fully aligned with strategic development goals.

EXPERIENCE IN BRONCHOALVEOLAR LAVAGE STUDIES FOR ANTI-INFECTIVE DRUG DEVELOPMENT

Clinartis possesses specialized expertise in conducting bronchoalveolar lavage (BAL) studies, which are crucial for the clinical development of anti-infective drugs targeting pulmonary infections. Our team brings extensive experience in conducting clinical trials assessing intrapulmonary penetration of investigational products in epithelial lining fluid (ELF) and alveolar macrophages (AM), providing critical insights into the therapeutic potential of anti-infective candidates for respiratory infectious diseases. This approach allows accurate assessment of drug activity against lung pathogens, especially in challenging infections such as pneumonia, bronchitis, and ventilator-associated pneumonia.

A deep understanding of the complexities involved in BAL studies enables effective navigation of challenges related to procedural standardization, ensuring safe bronchoscopy and bronchoalveolar lavage procedure, as well as high-quality sample collection and processing. Rigorous training of clinical staff and strict adherence to established protocols maintain the integrity of collected data. This disciplined approach ensures the consistency and reliability of samples while upholding the highest ethical and safety standards throughout the study process.

Leveraging extensive expertise in bronchoalveolar lavage and anti-infective drug development, Clinartis delivers comprehensive solutions that advance the understanding of drug performance in respiratory infections. A strong commitment to quality and innovation establishes Clinartis as a trusted partner in developing effective therapies that address critical unmet needs in treatment of pulmonary invectious diseases.

PHARMACOKINETIC STUDIES IN RENALLY AND HEPATICALLY IMPAIRED PATIENTS

Clinartis has extensive experience conducting pharmacokinetic studies in patients with renal and hepatic impairment, addressing the critical need for tailored drug dosing and safety assessments in these vulnerable populations. Our team is adept at designing and executing clinical trials that specifically evaluate how impaired renal or liver function affects the absorption, distribution, metabolism, and excretion of various therapeutics. We understand that pharmacokinetics can vary significantly in these patients, necessitating careful consideration of dosing regimens and potential drug interactions to minimize adverse effects and optimize therapeutic efficacy.

Our studies utilize advanced methodologies and robust statistical analyses to accurately assess pharmacokinetic parameters, ensuring that the results are both reliable and clinically relevant. By closely collaborating with regulatory authorities, we ensure that our studies comply with current guidelines and best practices, facilitating the development of drugs that are safe and effective for all patient populations. Clinartis prioritizes patient safety and data integrity, employing comprehensive monitoring and follow-up procedures to capture relevant clinical outcomes. Our expertise in this area positions us as a trusted partner for pharmaceutical and biotech companies looking to navigate the complexities of drug development in patients with renal and hepatic impairment. distribution, metabolism, and excretion of various therapeutics. We understand that pharmacokinetics can vary significantly in these patients, necessitating careful consideration of dosing regimens and potential drug interactions to minimize adverse effects and optimize therapeutic efficacy.

Our studies utilize advanced methodologies and robust statistical analyses to accurately assess pharmacokinetic parameters, ensuring that the results are both reliable and clinically relevant. By closely collaborating with regulatory authorities, we ensure that our studies comply with current guidelines and best practices, facilitating the development of drugs that are safe and effective for all patient populations. Clinartis prioritizes patient safety and data integrity, employing comprehensive monitoring and follow-up procedures to capture relevant clinical outcomes. Our expertise in this area positions us as a trusted partner for pharmaceutical and biotech companies looking to navigate the complexities of drug development in patients with renal and hepatic impairment.

CARDIAC SAFETY STUDIES

Clinartis has a robust track record in conducting cardiac safety studies, which are vital for evaluating the cardiovascular effects of new therapeutics across various indications. Our team is experienced in designing and managing clinical trials that assess the impact of drugs on cardiac function, with a particular focus on evaluating QT interval prolongation—a key indicator of potential cardiac risk. We utilize advanced methodologies such as thorough electrocardiogram (ECG) monitoring and telemetry to detect changes in cardiac rhythm and to assess the effects of pharmacotherapy on the QT interval. Recognizing the clinical significance of QT prolongation, we establish rigorous protocols to monitor this parameter closely, ensuring the safety of participants throughout the study.

Clinartis employs comprehensive cardiac safety assessment protocols that comply with regulatory requirements, addressing the critical safety concerns associated with new therapies that may prolong the QT interval. Our expertise allows us to effectively manage the logistical challenges of these studies, from patient recruitment and careful monitoring to robust data collection and analysis. By utilizing state-of-the-art technology and experienced clinical personnel, we provide high-quality, reliable data that informs both clinical decision-making and regulatory submissions.

Furthermore, we are well-versed in the evolving regulatory landscape regarding cardiac safety, including guidance from agencies such as the FDA and EMA concerning QT prolongation and its implications for drug approval. Clinartis’ commitment to safety and quality, combined with our in-depth knowledge of cardiac pharmacology, positions us as a trusted partner in advancing the development of therapeutics while ensuring that patient safety remains a top priority throughout the clinical trial process.

DRUG INTERACTIONS STUDIES

Understanding how drugs interact with other substances is crucial for patient safety and regulatory approval. Clinartis excels in conducting drug-drug, food-drug, and alcohol-drug interaction studies, delivering critical insights that shape prescribing guidelines and optimize therapeutic outcomes.

Evaluating pharmacokinetic and pharmacodynamic changes when investigational drugs are administered alongside other therapies is a key component of interaction research. Using cytochrome P450 enzyme profiling, transporter studies, and real-time clinical monitoring, Clinartis identifies potential metabolic alterations that could affect efficacy or safety.

Food-drug interaction studies help determine how meals influence drug absorption and bioavailability. By designing food-effect studies that compare pharmacokinetics under fed and fasting conditions, Clinartis generates data that ensures compliance with FDA and EMA standards and refines dosing instructions for maximum effectiveness.

Assessing the impact of alcohol consumption on drug metabolism and safety provides essential guidance for prescribing decisions. These studies identify whether alcohol affects a drug’s pharmacokinetics or adverse event profile, leading to appropriate safety warnings and usage recommendations.

Through advanced analytical techniques and strategic regulatory expertise, Clinartis ensures sponsors receive high-quality data that minimizes risks, enhances drug labeling, and supports successful clinical development.

ADME STUDIES IN HUMAN CLINICAL TRIALS

Clinartis’ includes design and execution of ADME (Absorption, Distribution, Metabolism, and Excretion) studies as part of early-phase clinical trials, which are often required to meet regulatory expectations for advancing clinical programs. These studies are essential for characterizing drug’s bioavailability, systemic exposure, metabolic profile, and elimination pathways. 

Clinartis collaborates with specialized clinical sites, bioanalytical and radiolabeling partners to support both non-radiolabeled and radiolabeled (e.g., [¹⁴C]) ADME studies, including human mass balance trials and metabolite profiling, in accordance with ICH and global regulatory standards. 

By leveraging real-time pharmacokinetic sampling, advanced LC-MS/MS platforms, and validated methods, we ensure accurate characterization of parent compounds and metabolites. This information is critical not only for optimizing dosing strategies but also for supporting regulatory filings, including INDs and NDAs, and addressing questions around drug-drug interactions and metabolic liabilities. 

Clinartis’ experienced project teams work closely with sponsors to align study objectives with clinical development timelines, enabling efficient data delivery and reducing operational risk. Our strategic approach integrates ADME insights into broader clinical decision-making, helping sponsors de-risk development, satisfy regulatory requirements, and accelerate time to market for novel therapeutics.

BIOEQUIVALENCE & BIOAVAILABILITY STUDIES

Clinartis provides end-to-end services for the design and execution of bioequivalence (BE) and bioavailability (BA) studies, supporting a wide range of product development strategies including generic drug approvals, formulation bridging, and 505(b)(2) regulatory submissions. These studies are essential for demonstrating pharmacokinetic comparability or establishing the systemic exposure of investigational products.

Our team is proficient in designing studies using standard two-period crossover, replicate crossover, and parallel group designs—tailored to the pharmacokinetic properties of the compound, variability expectations, and regulatory requirements. We routinely conduct studies under both fasted and fed conditions, as required by EMA, FDA, and other global agencies. 

Clinartis manages the full operational lifecycle of BE and BA studies—from protocol development and regulatory submission to clinical conduct, bioanalysis, and final reporting. We partner with high-quality clinical pharmacology units and validated bioanalytical laboratories to ensure precise data capture and rigorous statistical analysis. Our experience spans immediate- release, modified-release, fixed-dose combination, and locally acting products. 

For sponsors pursuing the 505(b)(2) pathway, Clinartis supports the generation of critical bridging data to reference listed drugs (RLDs), helping reduce the clinical burden and accelerate timelines. Our strategic approach integrates regulatory insight, study design optimization, and operational excellence to deliver studies that are cost-effective, compliant, and submission- ready.

Gallery

Contacts